Alberto Gabizon

7PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsSolid tumoursHaematological tumoursLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 26, 2026
A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer.

|Jan 31, 2025
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective.

Alberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi

|Jun 28, 2024
Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas.

Antonia Charalambous, Fotios Mpekris, Myrofora Panagi

|Sep 28, 2023
Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.

Md Rakibul Islam, Jalpa Patel, Patricia Ines Back

|Jul 08, 2022
Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.

Shira Dorot, James Tankel, Victoria Doviner

|Jul 10, 2020
Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines.

Alberto Gabizon, Janos Szebeni

Pageof 2

Frequent Collaborators

1 joint publications

Md Rakibul Islam

1 joint publications

Patricia Ines Back

1 joint publications

Claire Shudde

1 joint publications

Antonia Charalambous